Document
false0001356576 0001356576 2020-02-11 2020-02-11


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): February 11, 2020
 
Supernus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware
001-35518
20-2590184
 
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
 
 
 
1550 East Gude Drive
Rockville
MD
20850
 
(Address of Principal Executive Offices)
 
(Zip Code)
 

 
Registrant’s telephone number, including area code: (301) 838-2500
 
Not Applicable
(Former name or former address, if changed since last report.)

  Securities registered pursuant to Section 12(b) of the Exchange Act
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.001 par value per share
SUPN
The Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 

1



Item 2.02    Results of Operations and Financial Condition.
On February 11, 2020, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the fourth quarter and full year ended December 31, 2019 after 5:00 PM ET on Tuesday, February 25, 2020, and will host a conference call and webcast on Wednesday, February 26, 2020 to discuss its fourth quarter and full year 2019 business and financial results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

 
Item 9.01    Financial Statements and Exhibits.
 
(d)                                Exhibits.
    
The following document is furnished as an Exhibit pursuant to Item 8.01 hereof:
 
Exhibit 99.1- Press Release Dated February 11, 2020.

Exhibit 104 - The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.


2



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 
 
SUPERNUS PHARMACEUTICALS, INC.
 
 
DATED: February 11, 2020
By:
/s/ Gregory S. Patrick
 
 
Gregory S. Patrick
 
 
Senior Vice-President and Chief Financial Officer


3
Exhibit


Exhibit 99.1
 https://cdn.kscope.io/09aa90d06b687c37c78fc914ed99370c-logoa05.jpg
 

Supernus to Host Fourth Quarter and Full Year 2019 Results Earnings Conference Call

ROCKVILLE, Md., February 11, 2020 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business results for the fourth quarter and full year of 2019 after 5:00 p.m. ET on Tuesday, February 25, 2020.
Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Senior Vice President and Chief Financial Officer, will host a conference call to present the fourth quarter and full year of 2019 business and financial results on Wednesday, February 26, 2020 at 9:00 a.m. ET. Following management’s prepared analysis and discussion of business results, the call will be open for questions.

A live webcast will be available at www.supernus.com.

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

Conference dial-in:
(877) 288-1043
International dial-in:
(970) 315-0267
Conference ID:
7796907
Conference Call Name:
Supernus Pharmaceuticals Fourth Quarter and Full Year 2019 Earnings Conference Call
 
Following the live call, a replay will be available on the Company’s website under the ‘Investors Relations’ section. The webcast will be available on the Company’s website for 60 days following the live call.
 
About Supernus Pharmaceuticals, Inc.
 
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD and SPN-604 for the treatment of bipolar disorder.

CONTACT:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Or
Investor Contact:
Peter Vozzo
Westwicke, an ICR Company
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com